ABIVAX Société Anonyme (EPA:ABVX)
96.40
+2.80 (2.99%)
Apr 1, 2026, 9:43 AM CET
ABIVAX Société Anonyme Revenue
In the year 2025, ABIVAX Société Anonyme had annual revenue of 4.57M EUR, down -63.29%. ABIVAX Société Anonyme had revenue of 440.00K in the quarter ending December 31, 2025, a decrease of -89.79%.
Revenue
4.57M
Revenue Growth
-63.29%
P/S Ratio
1,621.82
Revenue / Employee
66.23K
Employees
67
Market Cap
7.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.57M | -7.88M | -63.29% |
| Dec 31, 2024 | 12.45M | 7.83M | 169.40% |
| Dec 31, 2023 | 4.62M | 38.00K | 0.83% |
| Dec 31, 2022 | 4.58M | -7.38M | -61.68% |
| Dec 31, 2021 | 11.96M | 10.31M | 624.91% |
| Dec 31, 2020 | 1.65M | 1.65M | 82,400.00% |
| Dec 31, 2019 | 2.00K | -812.00K | -99.75% |
| Dec 31, 2018 | 814.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 174.66M |
| Cellectis | 67.79M |
| Genfit | 45.13M |
| MedinCell | 32.44M |
| Inventiva | 16.97M |
| Nanobiotix | 10.16M |
| Transgene | 7.21M |
| Sensorion | 5.81M |
ABIVAX Société Anonyme News
- 5 days ago - 2 Healthcare Stocks That Could Soar Over the Next 5 Years - The Motley Fool
- 7 days ago - Abivax (ABVX) Shares Drop Amid Financials and Strategic Delays - GuruFocus
- 7 days ago - Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears - Benzinga
- 7 days ago - Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears - Benzinga
- 7 days ago - Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC - CNBC
- 11 days ago - 2 Healthcare Stocks to Buy Before They Get Bought Out - The Motley Fool
- 14 days ago - AMG TimesSquare Small Cap Growth Fund Q4 2025 Performance Insights - Seeking Alpha
- 15 days ago - Abivax: Maintaining 'Strong Buy' On Buyout Speculation And Obefazimod Advancement - Seeking Alpha